Cellectis S.A.

Cellectis S.A.

CMVLF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$349.25M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cellectis S.A.Cellectis S.A.-1.8-724%--10.2
$-1.19

Current Fair Value

134.3% downside

Overvalued by 134.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$349.25 Million
Enterprise Value$500.49 Million
Earnings per Share$-0.7
Beta3.06
Outstanding Shares100,647,451

Return

Return on Equity723.97%ROE
Return on Assets-59.81%
Return on Invested Capital-154.73%

Valuation & Multiples

P/E Ratio-1.78P/E Ratio
PEG0.02PEG
Price to Sales-Price to Sales
Price to Book Ratio-3.47Price to Book Ratio
Enterprise Value to Revenue19.88
Enterprise Value to EBIT-4.49
Enterprise Value to Net Income-4
Total Debt to Enterprise0.36
Debt to Equity-10.18Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 9, 2026
EPS Estimate
-$0.21
Consensus analyst estimate
Revenue Estimate
$15.02 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Cellectis

227 employees
CEO: Andre Choulika

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...

Questions & Answers